Soligenix Inc  

(Public, OTCBB:SNGX)   Watch this stock  
Find more results for OTC:SNGX
0.622
-0.048 (-7.16%)
Jun 29 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.62 - 0.69
52 week 0.44 - 2.48
Open 0.68
Vol / Avg. 172,435.00/115,810.00
Mkt cap 20.33M
P/E     -
Div/yield     -
EPS -0.17
Shares 31.47M
Beta 2.38
Inst. own 0%
Aug 10, 2016
Q2 2016 Soligenix Inc Earnings Release (Estimated) Add to calendar
May 12, 2016
Q1 2016 Soligenix Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -43.69% -89.31%
Operating margin -72.43% -81.09%
EBITD margin - -78.27%
Return on average assets -71.05% -109.21%
Return on average equity - -
Employees 16 -
CDP Score - -

Address

29 Emmons Dr Ste C10
PRINCETON, NJ 08540-5919
United States - Map
+1-609-5388200 (Phone)
+1-609-4526467 (Fax)

Website links

Description

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Officers and directors

Christopher J. Schaber Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 48
Joseph M. Warusz CPA Acting Chief Financial Officer, Vice President - Finance, Corporate Secretary
Age: 59
Oreola Donini Ph.D. Senior Vice President, Chief Scientific Officer
Age: 43
Richard C Straube M.D. Senior Vice President and Chief Medical Officer
Age: 63
Marco Maria Brughera Director
Age: 59
Keith L. Brownlie CPA Independent Director
Age: 62
Gregg A. Lapointe CPA Independent Director
Age: 56
Robert Joseph Rubin Independent Director
Age: 69
Jerome B. Zeldis M.D., Ph.D. Independent Director
Age: 65